Lannett Reports Insulin Glargine Trial Success
Ready To Present Trial Design For Lantus Rival To FDA
Lannett’s Phase I trial for biosimilar insulin glargine has met “all primary endpoints,” the company has announced. The rival to Sanofi’s Lantus is being developed by Lannett with partner HEC through a deal for which financial details have just been revealed.
